–Two-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients who Underwent the StemSpine® Procedure for Treating Chronic Lower Back Pain —
PHOENIX, Sept. 26, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, today announced the peer reviewed publication of positive, two-year follow-up data for the Company’s StemSpine® study, showing significant efficacy of the StemSpine® procedure for treating chronic lower back pain without any serious adverse effects reported.
The StemSpine® publication demonstrates the clinical use of the patented procedure that utilizes a patient’s own bone marrow aspirate for the treatment of chronic lower back pain. There were no safety related concerns at up to two years follow-up. The StemSpine® procedure resulted in an efficacy rate of 87% in the treated patients in terms of decreased pain and increased mobility.
“The positive two-year data from our StemSpine® study is very encouraging and may help alleviate the current opioid crisis related to prescription medication abuse for chronic lower back pain,” said Timothy Warbington, President and CEO of the Company. “To our knowledge, this is the first demonstration of the clinical efficacy of injecting bone marrow aspirate into areas surrounding the disc, which may repair, remodel and improve the blood supply around the disc and lower back area. We believe StemSpine® represents an attractive non-surgical option for many of the millions of Americans who suffer from chronic lower back pain and look forward to further translation.”
The StemSpine® patent also covers the use of off the shelf adult donor stem cells (allogeneic) for this indication.
The publication may be found at www.creativemedicaltechnology.com.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a biotechnology company specializing in regenerative medicine in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. For further information about the Company, please visit www.creativemedicaltechnology.com.
Forward Looking Statements
This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.
SOURCE Creative Medical Technology Holdings, Inc.
